Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Company Stock

Oruka Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Oruka Therapeutics insider Joana Goncalves sold 7,000 shares for $706,720 at an average price of $100.96, under a pre-arranged Rule 10b5-1 plan. She retained 31,771 shares after the sale, an 18.05% reduction in her holdings.
  • Oruka reported quarterly EPS of -$0.63, missing analyst expectations of -$0.60. Shares traded at $99.24, while analysts’ consensus rating was “Moderate Buy” with an average price target of $141.80.
  • Institutional investors own 56.44% of the company’s shares; several firms recently increased or initiated positions, including BlackRock, which purchased a stake valued at about $475 million.
  • Five stocks we like better than Oruka Therapeutics.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $100.96, for a total value of $706,720.00. Following the completion of the transaction, the insider directly owned 31,771 shares in the company, valued at $3,207,600.16. This trade represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

  • On Thursday, October 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $74.81, for a total value of $523,670.00.
  • On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA traded down $6.11 during mid-day trading on Monday, hitting $99.24. The stock had a trading volume of 989,987 shares, compared to its average volume of 1,082,544. Oruka Therapeutics, Inc. has a 1 year low of $25.23 and a 1 year high of $115.51. The business has a 50 day moving average price of $89.68 and a two-hundred day moving average price of $72.36. The firm has a market cap of $6.73 billion, a P/E ratio of -47.03 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). Equities research analysts predict that Oruka Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Guggenheim reaffirmed a "buy" rating and set a $200.00 price target on shares of Oruka Therapeutics in a research report on Monday, October 26th. BTIG Research reiterated a "buy" rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 10th. Finally, Wedbush reiterated an "outperform" rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $141.80.

Get Our Latest Stock Analysis on Oruka Therapeutics

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Oruka Therapeutics during the second quarter valued at $474,916,000. Remedium Capital Partners LLC boosted its holdings in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company's stock valued at $76,796,000 after buying an additional 13,247 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $130,968,000. Avidity Partners Management LP grew its position in shares of Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company's stock worth $37,299,000 after buying an additional 100,000 shares during the period. Finally, Voya Investment Management LLC grew its position in shares of Oruka Therapeutics by 2.9% in the 3rd quarter. Voya Investment Management LLC now owns 412,814 shares of the company's stock worth $34,383,000 after buying an additional 11,665 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Featured Articles

Insider Buying and Selling by Quarter for Oruka Therapeutics (NASDAQ:ORKA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oruka Therapeutics Right Now?

Before you consider Oruka Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.

While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines